Eisai, Biogen say Alzheimer's drug Lecanemab getting priority review in China

[February 28, 2023]  TOKYO (Reuters) - Japanese drugmaker Eisai Co Ltd and U.S. biotech firm Biogen Inc said on Tuesday that Chinese authorities have given priority review status to Lecanemab, their jointly-developed Alzheimer's disease treatment drug.

The drug, recently granted accelerated approval in Japan, is an antibody that has been shown to remove sticky deposits of a protein called amyloid beta from the brains of patients in the early stages of the mind-wasting disease.

(Reporting by Mariko Katsumura; Editing by Tom Hogue)

The logo of Eisai Co Ltd is displayed at the company headquarters in Tokyo, Japan, March 8, 2018. REUTERS/Issei Kato

[© 2023 Thomson Reuters. All rights reserved.]This material may not be published, broadcast, rewritten or redistributed.  Thompson Reuters is solely responsible for this content.